Evidence map›Paper›PMID 40223040›Full record

ArticleJournal of the Egyptian National Cancer Institute2025

Health-related quality of life and survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization and Yttrium-90.

Kathryn Bress, Patrick Bou-Samra, Cramer J Kallem, Allan Tsung, Ellie Gammer, David A Geller, James W Marsh, Jennifer L Steel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kathryn BressDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Patrick Bou-SamraDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Cramer J KallemDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Allan TsungDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ellie GammerDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
David A GellerDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
James W MarshDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Jennifer L SteelDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. steejl@upmc.edu.ORCID http://orcid.org/0000-0001-9520-963X

Funding

Comprehensive Electronic Support System for Treatment of Cancer-Related SymptomsK07CA118576 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEEL, JENNIFER L. · 2006 to 2010
$757k
NCI NIH HHS 07CA118576NCI NIH HHS K07 CA118576NCI NIH HHS K07CA118576-04S1
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Due to the advanced stage in which HCC presents, most patients are only eligible for transarterial chemoembolization (TACE) or radioembolization (Y

methodsTwo hundred thirty-four patients with HCC were enrolled in studies examining HRQOL between 2003-2009. HRQOL was evaluated using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep). Between-group differences were examined using chi-square and ANOVA. Survival was assessed using Kaplan-Meier and Cox regression analyses.

resultsSignificant baseline differences between patients treated with TACE versus Y

conclusionsTreatment with TACE and Y

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsQuality of LifeYttrium RadioisotopesAdultAgedFemaleHumansKaplan-Meier EstimateMaleMiddle AgedTreatment OutcomeYttrium-90Yttrium RadioisotopesHealth-related quality of lifeHepatocellular carcinomaRadioembolizationSurvival analysisTransarterial chemoembolization

Identifiers

PMID40223040
PMCPMC11994534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.